Last reviewed · How we verify
Cabotegravir Injection
Cabotegravir Injection is a Small molecule drug developed by Duke University. It is currently FDA-approved. Also known as: brand name: Apretude, Oral cabotegravir, Apretude.
At a glance
| Generic name | Cabotegravir Injection |
|---|---|
| Also known as | brand name: Apretude, Oral cabotegravir, Apretude |
| Sponsor | Duke University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men (PHASE2, PHASE3)
- Long-acting Cabotegravir Injectable Pre-exposure Prophylaxis for People Who Inject Drugs (PHASE4)
- Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1 (PHASE3)
- Tshireletso: Safety, Efficacy and Feasibility of Cabotegravir-LA PrEP in a Breastfeeding Population in Botswana (PHASE4)
- HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cabotegravir Injection CI brief — competitive landscape report
- Cabotegravir Injection updates RSS · CI watch RSS
- Duke University portfolio CI
Frequently asked questions about Cabotegravir Injection
What is Cabotegravir Injection?
Cabotegravir Injection is a Small molecule drug developed by Duke University.
Who makes Cabotegravir Injection?
Cabotegravir Injection is developed and marketed by Duke University (see full Duke University pipeline at /company/duke-university).
Is Cabotegravir Injection also known as anything else?
Cabotegravir Injection is also known as brand name: Apretude, Oral cabotegravir, Apretude.
What development phase is Cabotegravir Injection in?
Cabotegravir Injection is FDA-approved (marketed).
Related
- Manufacturer: Duke University — full pipeline
- Also known as: brand name: Apretude, Oral cabotegravir, Apretude
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing